• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Drug Compounding: Background, Issues & FDA Oversight

Drug Compounding: Background, Issues & FDA Oversight

9781631173608
661,44 zł
595,29 zł Zniżka 66,15 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 595,29 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Compounding has been traditionally defined as a process where a pharmacist or a physician combines, mixes, or alters ingredients to create a medication tailored to the needs of an individual patient. Traditionally compounded drugs (CDs) are made in response to an individual prescription from a licensed health provider in the context of a pharmacists and health care professionals relationship with a specific patient. This book provides background information on CDs and non-traditional compounding pharmacies relevant to policy discussions. This book will also examine the FDAs regulation of drug compounding and will discuss relevant legal authorities. Specifically, the status of FDAs authority to oversee drug compounding, and the gaps, if any, between state and federal authority will be discussed, as well as how FDA has used its data and authority to oversee drug compounding, and the actions taken or planned by states or national pharmacy organisations to improve oversight of drug compounding.
Szczegóły produktu
74521
9781631173608
9781631173608

Opis

Rok wydania
2014
Numer wydania
1
Oprawa
twarda
Liczba stron
123
Wymiary (mm)
155.00 x 230.00
Waga (g)
382
  • Preface; Compounded Drugs; Federal Authority to Regulate the Compounding of Human Drugs; Drug Compounding:: Clear Authority & More Reliable Data Needed to Strengthen FDA Oversight; Statement of Janet Woodcock, Director, Center for Drug Evaluation & Research, Food & Drug Administration. Hearing on Examining Drug Compounding; Testimony of Scott Gottlieb, Resident Fellow, The American Enterprise Institute. Hearing on Examining Drug Compounding; Testimony of Joe Harminson, Owner of DFW Prescriptions, on behalf of the National Community Pharmacists Association. Hearing on Examining Drug Compounding; Index.
Komentarze (0)